Foghorn Therapeutics Inc logo
FHTXFoghorn Therapeutics Inc
Trade FHTX now
Foghorn Therapeutics Inc primary media

About Foghorn Therapeutics Inc

Foghorn Therapeutics (NASDAQ:FHTX) harnesses its pioneering Gene Traffic Control™ platform to discover and develop innovative therapies targeting diseases with a genetic basis, particularly cancer. The company's mission is centered around unlocking the vast potential of the human genome to revolutionize treatment options for patients battling these serious conditions. Through a deep understanding of chromatin biology, Foghorn Therapeutics strives to lead the way in creating a new wave of precision medicine. Their projects range from early discovery to clinical development, emphasizing a commitment to bringing groundbreaking treatments from the lab bench to bedside.

What is FHTX known for?

Snapshot

Public US
Ownership
2015
Year founded
131
Employees
Massachusetts, United States
Head office
Loading Map...

Operations

All Locations
United States

Products and/or services of Foghorn Therapeutics Inc

  • FHD-286 for treatment of myeloid leukemia and solid tumors, aiming at enzymatic activity modulation of BRG1 and BRM, part of the chromatin remodeling complex.
  • FHD-609, a targeted protein degradation approach focused on inhibiting BRD9, a component of the non-canonical BAF (ncBAF) complex, for treating synovial sarcoma and SMARCB1-null tumors.
  • Gene Traffic Control platform, leveraging proprietary insights into the Chromatin Regulatory System to identify novel drug targets and understand disease mechanisms.
  • Collaboration with multiple biopharmaceutical companies to use the Gene Traffic Control platform for discovering novel therapeutic targets in various diseases.
  • Development of small molecule inhibitors targeting the chromatin remodeling complexes to treat cancers with specific genetic alterations.
  • Investigation into the role of chromatin dysregulation in cancer to identify potential therapeutic targets and biomarkers for novel treatments.

Foghorn Therapeutics Inc executive team

  • Mr. Adrian H. B. GottschalkPresident, CEO & Director
  • Dr. Anna Rivkin Ph.D.Chief Business Officer
  • Dr. Gerald R. Crabtree M.d.Founder & Member of Scientific Advisory Board
  • Mr. Jeffrey A. Sacher M.B.A.Interim CFO & Treasurer
  • Dr. Steven F. Bellon Ph.D.Chief Scientific Officer
  • Ms. Karin HellsvikChief of Staff to the CEO, VP of Corporate Affairs & Investor Relations
  • Mr. Michael J. LaCascia J.D.Chief Legal Officer
  • Mr. Saurabh Sewak Ph.D.Vice President of Corporate Development
  • Mr. Carlos CostaChief People Officer
  • Dr. Alfonso Quintas Cardama M.D.Chief Medical Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.